Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Senior who wrote (34976)	9/28/2009 12:44:29 PM
From: E_K_S	Read Replies (1) of 78666

Welcome back Paul - It's not very often that the buyer goes up after an acquisition, especially the size of this one. ABT up 3.2% on their announcement. Abbott to buy Solvay drug business for up to $7 billion Deal gives Abbott control over cholesterol drug franchise marketwatch.com From the article:"...The deal, which is expected to close in the first quarter of 2010, will add around 10 cents to Abbott's adjusted earnings per share in 2010, rising to 20 cents by 2012. Abbott said it plans to pay for the acquisition with cash from its balance sheet...." ============================================================== Good job on your persistent buys of ABT. I opted to buy LLY based on current price and forward PE. It appears LLY plans to increase their revenues through downsizing while ABT's approach will be to buy into the future pipeline of new drugs. The market seems to like ABT's approach more so than LLY's. EKS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next